Phase 2 Data of Dipraglurant for Parkinson’s-associated, Levodopa-induced Dyskinesia Announced by Addex
Addex Therapeutics recently published the results of the company’s Phase 2 trial of its drug candidate dipraglurant in patients with levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). The manuscript, “A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson’s Disease,” was published…